Stock Traders Purchase Large Volume of Put Options on Keros Therapeutics (NASDAQ:KROS)

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) was the target of unusually large options trading activity on Friday. Stock investors acquired 4,215 put options on the company. This represents an increase of approximately 287% compared to the typical volume of 1,090 put options.

Insiders Place Their Bets

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the business's stock in a transaction dated Wednesday, April 9th. The stock was acquired at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the transaction, the insider now directly owns 4,392,737 shares of the company's stock, valued at $44,498,425.81. This represents a 27.01 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 22.90% of the company's stock.

Institutional Trading of Keros Therapeutics

Several institutional investors have recently made changes to their positions in KROS. Vanguard Group Inc. increased its stake in Keros Therapeutics by 5.4% during the fourth quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company's stock worth $30,981,000 after acquiring an additional 100,691 shares during the last quarter. Braidwell LP increased its position in shares of Keros Therapeutics by 167.9% during the 4th quarter. Braidwell LP now owns 1,894,439 shares of the company's stock worth $29,989,000 after purchasing an additional 1,187,199 shares during the last quarter. Darwin Global Management Ltd. raised its holdings in Keros Therapeutics by 10.7% in the 4th quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company's stock valued at $26,707,000 after buying an additional 163,403 shares during the period. Millennium Management LLC lifted its position in Keros Therapeutics by 53.3% in the fourth quarter. Millennium Management LLC now owns 878,159 shares of the company's stock valued at $13,901,000 after buying an additional 305,169 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Keros Therapeutics by 5.5% during the fourth quarter. Geode Capital Management LLC now owns 765,436 shares of the company's stock worth $12,120,000 after buying an additional 39,815 shares during the period. Hedge funds and other institutional investors own 71.56% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on KROS shares. Oppenheimer cut their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a report on Thursday, January 16th. Truist Financial cut their target price on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research note on Wednesday, April 9th. Guggenheim reaffirmed a "neutral" rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Piper Sandler cut their price objective on Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research note on Friday, January 17th. Finally, Wells Fargo & Company reduced their target price on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, February 27th. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $40.33.

Keros Therapeutics Stock Up 2.9 %

Shares of KROS traded up $0.38 during midday trading on Wednesday, reaching $13.47. The company had a trading volume of 573,039 shares, compared to its average volume of 773,222. Keros Therapeutics has a 1-year low of $9.12 and a 1-year high of $72.37. The firm has a 50 day simple moving average of $10.97 and a 200-day simple moving average of $30.19. The stock has a market cap of $546.37 million, a PE ratio of -2.59 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.36) by $0.22. The firm had revenue of $3.04 million during the quarter, compared to analysts' expectations of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. As a group, sell-side analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.